Heart failure in COVID‐19: the multicentre, multinational PCHF‐COVICAV registry
Genre
Journal articleDate
2021-09-17Author
Sokolski, MateuszTrenson, Sander
Sokolska, Justyna M.
D'Amario, Domenico
Meyer, Philippe
Poku, Nana K.
Biering-Sørensen, Tor
Højbjerg Lassen, Mats C.
Skaarup, Kristoffer G.
Barge-Caballero, Eduardo
Pouleur, Anne-Catherine
Stolfo, Davide
Sinagra, Gianfranco
Ablasser, Klemens
Muster, Viktoria
Rainer, Peter P.
Wallner, Markus

Chiodini, Alessandra
Heiniger, Pascal S.
Mikulicic, Fran
Schwaiger, Judith
Winnik, Stephan
Cakmak, Huseyin A.
Gaudenzi, Margherita
Mapelli, Massimo
Mattavelli, Irene
Paul, Matthias
Cabac-Pogorevici, Irina
Bouleti, Claire
Lilliu, Marzia
Minoia, Chiara
Dauw, Jeroen
Costa, Jérôme
Celik, Ahmet
Mewton, Nathan
Montenegro, Carlos E.L.
Matsue, Yuya
Loncar, Goran
Marchel, Michal
Bechlioulis, Aris
Michalis, Lampros
Dörr, Marcus
Prihadi, Edgard
Schoenrath, Felix
Messroghli, Daniel R.
Mullens, Wilfried
Lund, Lars H.
M.C. Rosano, Giuseppe
Ponikowski, Piotr
Ruschitzka, Frank
Flammer, Andreas J.
Department
MedicinePermanent link to this record
http://hdl.handle.net/20.500.12613/6975
Metadata
Show full item recordDOI
https://doi.org/10.1002/ehf2.13549Abstract
Aims: We assessed the outcome of hospitalized coronavirus disease 2019 (COVID-19) patients with heart failure (HF) compared with patients with other cardiovascular disease and/or risk factors (arterial hypertension, diabetes, or dyslipidaemia). We further wanted to determine the incidence of HF events and its consequences in these patient populations. Methods and results: International retrospective Postgraduate Course in Heart Failure registry for patients hospitalized with COVID-19 and CArdioVascular disease and/or risk factors (arterial hypertension, diabetes, or dyslipidaemia) was performed in 28 centres from 15 countries (PCHF-COVICAV). The primary endpoint was in-hospital mortality. Of 1974 patients hospitalized with COVID-19, 1282 had cardiovascular disease and/or risk factors (median age: 72 [interquartile range: 62–81] years, 58% male), with HF being present in 256 [20%] patients. Overall in-hospital mortality was 25% (n = 323/1282 deaths). In-hospital mortality was higher in patients with a history of HF (36%, n = 92) compared with non-HF patients (23%, n = 231, odds ratio [OR] 1.93 [95% confidence interval: 1.44–2.59], P < 0.001). After adjusting, HF remained associated with in-hospital mortality (OR 1.45 [95% confidence interval: 1.01–2.06], P = 0.041). Importantly, 186 of 1282 [15%] patients had an acute HF event during hospitalization (76 [40%] with de novo HF), which was associated with higher in-hospital mortality (89 [48%] vs. 220 [23%]) than in patients without HF event (OR 3.10 [2.24–4.29], P < 0.001). Conclusions: Hospitalized COVID-19 patients with HF are at increased risk for in-hospital death. In-hospital worsening of HF or acute HF de novo are common and associated with a further increase in in-hospital mortality.Citation to related work
Wiley Open AccessHas part
ESC Heart Failure, 2021ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.eduae974a485f413a2113503eed53cd6c53
http://dx.doi.org/10.34944/dspace/6956
Scopus Count
Collections
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs CC BY-NC-ND